Unknown

Dataset Information

0

Immuno-PET Imaging of the Programmed Cell Death-1 Ligand (PD-L1) Using a Zirconium-89 Labeled Therapeutic Antibody, Avelumab.


ABSTRACT:

Objective

The goal is to evaluate avelumab, an anti-PD-L1 monoclonal immunoglobulin G antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse xenografts for clinical translation.

Methods

[89Zr]Zr-DFO-PD-L1 monoclonal antibody (mAb) was synthesized using avelumab conjugated to desferrioxamine. In vitro binding studies and biodistribution studies were performed with PD-L1+MDA-MB231 cells and MDA-MB231 xenograft mouse models, respectively. Biodistributions were determined at 1, 2, 3, 5, and 7 days post coinjection of [89Zr]Zr-DFO-PD-L1 mAb without or with unlabeled avelumab (10, 20, 40, and 400 µg).

Results

[89Zr]Zr-DFO-PD-L1 mAb exhibited high affinity (Kd ? 0.3 nM) and detected moderate PD-L1 expression levels in MDA-MB231 cells. The spleen and lymph nodes exhibited the highest [89Zr]Zr-DFO-PD-L1 mAb uptakes in all time points, while MDA-MB231 tumor uptakes were lower but highly retained. In the unlabeled avelumab dose escalation studies, spleen tissue-muscle ratios decreased in a dose-dependent manner indicating specific [89Zr]Zr-DFO-PD-L1 mAb binding to PD-L1. In contrast, lymph node and tumor tissue-muscle ratios increased 4- to 5-fold at 20 and 40 µg avelumab doses.

Conclusions

[89Zr]Zr-DFO-PD-L1 mAb exhibited specific and high affinity for PD-L1 in vitro and had target tissue uptakes correlating with PD-L1 expression levels in vivo. [89Zr]Zr-DFO-PD-L1 mAb uptake in PD-L1+tumors increased with escalating doses of avelumab.

SUBMITTER: Jagoda EM 

PROVIDER: S-EPMC6498777 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Objective</h4>The goal is to evaluate avelumab, an anti-PD-L1 monoclonal immunoglobulin G antibody labeled with zirconium-89 in human PD-L1-expressing cancer cells and mouse xenografts for clinical translation.<h4>Methods</h4>[<sup>89</sup>Zr]Zr-DFO-PD-L1 monoclonal antibody (mAb) was synthesized using avelumab conjugated to desferrioxamine. In vitro binding studies and biodistribution studies were performed with PD-L1+MDA-MB231 cells and MDA-MB231 xenograft mouse models, respectively. Biodi  ...[more]

Similar Datasets

| S-EPMC3637856 | biostudies-literature
| S-EPMC6244539 | biostudies-literature
| S-EPMC5341755 | biostudies-literature
| S-EPMC10193402 | biostudies-literature
| S-EPMC6805423 | biostudies-literature
| S-EPMC6521698 | biostudies-literature
| S-EPMC6175665 | biostudies-literature
| S-EPMC4877495 | biostudies-literature
| S-EPMC6780657 | biostudies-literature
| S-EPMC6474755 | biostudies-literature